Those of us following cancer news wait with baited breath for news of cures and treatments with promising results. So it's always a bit of a disappointment when it's bad news, like this: New Zealand researches and determined that the clinical trails on an Ovarian Cancer Drug called DMXAA have not demonstrated any positive results. The premise behind the drug was that it could kill cancer by reducing the blood supply to tumors, and it was given to Ovarian Cancer patients, along with Chemotherapy, to see if it would make a difference in recovery. Unfortunately, it didn't, and research on Ovarian cancer will be put on the backburner to make way for Lung Cancer trials at Novartis in New Zealand.
